Immunitybio Inc (IBRX) Stock Price, Quote & News

Company Profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 696 5235

Website: immunitybio.com

Address:

3530 John Hopkins Court, San Diego, United States

LB19 Mar. 15 at 10:19 AM

$IBRX in bed with big pharma.

0 · Reply

Breakthru Mar. 15 at 9:31 AM

$IBRX this is just a thought and possibly off base. But what if the real reason behind not approving IBRX ‘s drug is about litigation? Is the FDA worried that if they approve IBRX’s drug that brings back one’s immune system, they are admitting that chemo/radiation destroys it. Thereby formally admitting that people can die (or are dying) from chemo/radiation toxicity and not from the cancer. Are they worried that lawsuits will start to occur?

3 · Reply

BustedAgain Mar. 15 at 9:23 AM

$IBRX blocked

0 · Reply

Badnanny Mar. 15 at 8:57 AM

$IBRX here's chat gpts take:

4 · Reply

Bc3345 Mar. 15 at 8:19 AM

$IBRX help me understand, please help me? 🙏 “Search instead for did they ask nato for help keeping the straight of hormuz open AI Overview As of mid-March 2026, amid soaring tensions and conflict with Iran, Donald Trump has called upon international allies, including NATO members, to deploy naval task forces to the Strait of Hormuz to keep the shipping lanes open. Facebook Facebook +1 Key Details of the Request: Call for Action: Trump stated on Truth Social that "The Countries of the World that receive Oil through the Hormuz Strait must take care of that passage" and urged nations to send warships to safeguard the area.”

0 · Reply

svertical1 Mar. 15 at 8:02 AM

$IBRX It’s clear Dr Makary is making long needed Policy changes at FDA. How many promising Biotech’s and drugs failed because they lacked the capital to fight through the Death Cult. Delays cost Death and Mutilation and can be measured. See Grok below for Bladder alone. Anktiva will not save everyone, and would be more effective if not relegated to 3rd line failure. Regardless, past time to approve, All Cancer! https://grok.com/share/c2hhcmQtMw_ef82ac97-f3e4-4fe0-9746-7ee128d0a1e1

1 · Reply

LB19 Mar. 15 at 7:10 AM

$IBRX what I hope to see happen asap is vast rapid approvals "under mechanism of action" which the NIH director recently discussed. There is a recent job posting that signals this is coming, I'm 🙏 that it does. Some notable points are... *Educate provider practices, including physicians, nurses, pharmacists, and clinical staff, on Anktiva’s mechanism of action, indication, patient selection criteria, and administration per the FDA-approved label. *Teach provider offices how to create a Center for Excellence, specific to treatment with Anktiva. *Coordinate with Market Access and Operations teams to support site onboarding, access readiness, and reimbursement education *Experience supporting product launches or new therapy adoption is preferred https://nant.wd5.myworkdayjobs.com/en-US/ImmunityBio/job/Remote/Clinical-Implementation-Director_R2863

0 · Reply

winners3628 Mar. 15 at 6:57 AM

$IBRX 2017 https://www.fiercebiotech.com/biotech/patrick-soon-shiong-channelling-trump-user-twitter-to-vent-anger-over-attacks

4 · Reply

LB19 Mar. 15 at 6:09 AM

$IBRX This story made me cry, is unbelievably horrible what is going on in this country. I will explain. Patrick on Twitter responded to a plea for help to save a mom's daughter. All wonderful right? No. Not only is PROVEN cancer treatment not being approved, you also have to apply and WAIT for approval under FDA's Investigational New Drug process to try to get it. Imagine being told you have to wait 30 days for approval while on deaths door and cancer is spreading. It's beyond cruel 💔 So Nov 25th Patrick said he will help as fast as he can. Jan 3rd mom posts they were within days with starting treatment with Patrick but it is now too late. Jan 14th the little girl is gone. I cannot imagine what Patrick must be going through mentally and emotionally with all these kinds of cases all the time. To watch what must be countless people over and over again plea for help and then DIE whom you didn't even have an opportunity to try to help because of FDA roadblocks. Imagine knowing you can relieve suffering but the FDA has your hands tied. Patrick gave effort to save this girl's life but after all the waiting because of FDA it was too late 💔😭 We must demand change, this ain't right!!

4 · Reply

4RUNNA Mar. 15 at 5:54 AM

$IBRX LETS GET IT THEN !

0 · Reply

Why Is ImmunityBio Stock Soaring On Friday?

Mar 13, 2026, 7:30 AM EDT - 1 day ago

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Mar 9, 2026, 11:03 AM EDT - 5 days ago

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

Mar 9, 2026, 7:30 AM EDT - 5 days ago

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Mar 3, 2026, 11:52 PM EST - 11 days ago

ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript

Feb 27, 2026, 7:30 AM EST - 15 days ago

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

Feb 26, 2026, 8:57 AM EST - 16 days ago

ImmunityBio Investors Rally Behind Cancer Trial Milestone

Feb 26, 2026, 7:30 AM EST - 16 days ago

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 25, 2026, 1:02 PM EST - 17 days ago

ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

Feb 25, 2026, 9:09 AM EST - 17 days ago

ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate

Feb 23, 2026, 4:15 PM EST - 19 days ago

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

Feb 23, 2026, 12:34 PM EST - 19 days ago

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

Feb 23, 2026, 7:31 AM EST - 19 days ago

Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More

AEM LITE

Feb 23, 2026, 7:00 AM EST - 19 days ago

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

Feb 20, 2026, 8:30 AM EST - 22 days ago

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

Feb 19, 2026, 11:37 AM EST - 23 days ago

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

Feb 19, 2026, 9:00 AM EST - 23 days ago

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

Feb 18, 2026, 12:02 PM EST - 24 days ago

What's Behind The Jump In ImmunityBio Stock?

Feb 18, 2026, 9:00 AM EST - 24 days ago

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

Feb 18, 2026, 5:12 AM EST - 25 days ago

ImmunityBio: The Story Surrounding Anktiva So Far

Feb 17, 2026, 6:07 AM EST - 25 days ago

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

Feb 2, 2026, 2:08 PM EST - 5 weeks ago

These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More

CAR KSS LCID CHH HIMS MARA MPT

Feb 2, 2026, 7:00 AM EST - 5 weeks ago

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

Jan 23, 2026, 7:00 AM EST - 7 weeks ago

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

Jan 20, 2026, 1:47 PM EST - 7 weeks ago

FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer

Jan 20, 2026, 8:46 AM EST - 7 weeks ago

Top 3 Health Care Stocks You May Want To Dump In January

Jan 20, 2026, 4:00 AM EST - 7 weeks ago

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

Jan 16, 2026, 3:45 PM EST - 2 months ago

ImmunityBio, Inc. (IBRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 16, 2026, 12:52 PM EST - 2 months ago

ImmunityBio Stock Soars On Cancer Trial Progress, FDA Timeline

Jan 16, 2026, 11:04 AM EST - 2 months ago

ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So

Jan 16, 2026, 10:41 AM EST - 2 months ago

Looking For A Short Squeeze? 10 Stocks Ready To Rocket

CAR CHH HIMS KSS LCID MARA PCT

Jan 16, 2026, 7:00 AM EST - 2 months ago

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

Jan 16, 2026, 7:00 AM EST - 2 months ago

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

Jan 16, 2026, 5:52 AM EST - 2 months ago

This Biotech Stock Is Up 100% This Year. Why It's Soaring Again Today.

Jan 15, 2026, 12:50 PM EST - 2 months ago

ImmunityBio: Why I Am Upgrading To A Buy For 2026

Jan 15, 2026, 12:43 PM EST - 2 months ago

ImmunityBio Clocks 700% Revenue Surge In 2025 From Lead Bladder Cancer Drug

Jan 15, 2026, 8:30 AM EST - 2 months ago

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

Jan 14, 2026, 8:30 AM EST - 2 months ago

Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

Jan 14, 2026, 8:30 AM EST - 2 months ago

Saudi FDA Grants Accelerated Approval to ImmunityBio's ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Jan 13, 2026, 8:30 AM EST - 2 months ago

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Jan 12, 2026, 8:30 AM EST - 2 months ago

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

Dec 29, 2025, 9:00 AM EST - 2 months ago

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

Dec 16, 2025, 9:00 AM EST - 3 months ago

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

Dec 12, 2025, 12:00 PM EST - 3 months ago

ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy

Dec 12, 2025, 6:10 AM EST - 3 months ago

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

Dec 3, 2025, 5:00 AM EST - 3 months ago

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs

Nov 19, 2025, 4:56 AM EST - 4 months ago

ImmunityBio: Checking The Boxes Of A True Commercial-Stage Biotech

Nov 13, 2025, 9:00 AM EST - 4 months ago

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

LB19 Mar. 15 at 10:19 AM

$IBRX in bed with big pharma.

0 · Reply

Breakthru Mar. 15 at 9:31 AM

3 · Reply

BustedAgain Mar. 15 at 9:23 AM

$IBRX blocked

0 · Reply

Badnanny Mar. 15 at 8:57 AM

$IBRX here's chat gpts take:

4 · Reply

Bc3345 Mar. 15 at 8:19 AM

0 · Reply

svertical1 Mar. 15 at 8:02 AM

1 · Reply

LB19 Mar. 15 at 7:10 AM

0 · Reply

winners3628 Mar. 15 at 6:57 AM

$IBRX 2017 https://www.fiercebiotech.com/biotech/patrick-soon-shiong-channelling-trump-user-twitter-to-vent-anger-over-attacks

4 · Reply

LB19 Mar. 15 at 6:09 AM

4 · Reply

4RUNNA Mar. 15 at 5:54 AM

$IBRX LETS GET IT THEN !

0 · Reply

Ssssandhu Mar. 15 at 5:31 AM

$IBRX @FrankMolar Friday trend was postive bcz of good news about World bank of NK cells. Only reason we didn’t get full outcome of good news Bcz it was weekend. Also; there was good volume overall and specially big buys at the close; which will show some good strength and momentum on monday. Finger cross if we get any new news about anything and plus news from friday; its going to move sharply means it will literally force shorts to cover. Last time when it gave us first pump we went to $8 from 3 and then we got push back to $6 Second pump took us to $12.4 and pushback got us to $8. All the weak hands are gone Third pump is going to be real one and we going to break 52 week high again. Hold guys dont sell. Lets shorts to regret

1 · Reply

1kaffee Mar. 15 at 4:59 AM

$IBRX Nice posts/comments from board members. Thank you .

1 · Reply

svertical1 Mar. 15 at 4:10 AM

$IBRX 30K+ Followers on X! https://x.com/thomas_james_1/status/2032995288252576053?s=42

0 · Reply

Watchingnow Mar. 15 at 4:03 AM

$IBRX a bit puzzled. Apparently there are no side effects and its safe. Whats the issue thats holding up approvals for other cancers?

6 · Reply

LB19 Mar. 15 at 3:49 AM

$IBRX 👌

0 · Reply

LB19 Mar. 15 at 3:01 AM

$IBRX I believe in my heart we will succeed. It's beyond the validated data. I've heard Patrick say this is his life's purpose, to defeat Cancer. He will stop at nothing until the job is done!

1 · Reply

Whatever2020 Mar. 15 at 2:52 AM

$IBRX Immunitybio's Anktiva + BCG in first line (naive) nmibc has demonstrated a 100% complete response (CR) at nearly 10 years after treatment. This has never been seen before in this indication. It is vastly superior to current standard of care and should replace that current standard immediately.

2 · Reply

LB19 Mar. 15 at 2:49 AM

$IBRX Pretty epic that when Patrick was young he met senator Robert F. Kennedy in South Africa. Now now 60 years later he's working to cure Cancer and Robert F Kennedy's son RFK jr is the Secretary of Health and Human services! 🤯

0 · Reply

Whatever2020 Mar. 15 at 2:47 AM

$IBRX As of now, Anktiva + BCG beats all competitors in nmibc. The closest one is Johnson&Johnson's "INLEXZO". Anktiva has a 10% better bladder preservation at 24 months. Inlexzo does not have 36 month data, but it's likely their data will fall further behind Anktiva's published 36 month data. Let's not forget that Inlexzo is a chemotherapy with an array of side effects that are absent in Anktiva + BCG. A question i have is why a subcutaneous injection of Anktiva is not given in conjunction with the intravesical (into bladder).

0 · Reply

Intime32 Mar. 15 at 2:36 AM

$IBRX I believe the Future, check your ALC @ Home Basically like Blood Sugar, By Phone or old Finger Prick, if Low Go over to Med Cabinet grab your low Dose Anktiva pills or Machine Made NK Cell Booster, take till ALC is 1500 area, just monitor monthly, all Humans world Population the Fountain of Youth has Been FOUND!

1 · Reply

burchrealtync Mar. 15 at 2:24 AM

$IBRX I like it! laugh!

0 · Reply

Td5650 Mar. 15 at 2:10 AM

$IBRX

0 · Reply

Market Cap	8.63B
Revenue (ttm)	113.29M
Net Income (ttm)	-351.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-310.18%
Debt to Equity Ratio	0.00

Volume	30,623,201
Avg Vol	40,914,508
Day's Range	N/A - N/A
Shares Out	1.03B
Stochastic %K	22%
Beta	-0.03
Analysts	Strong Sell
Price Target	$14.80